tailieunhanh - Calprotectin in cystic fibrosis

There is increasing evidence that intestinal inflammation plays a major role in gastrointestinal symptoms in cystic fibrosis (CF). Fecal calprotectin is a marker that is elevated in several gastrointestinal inflammatory diseases, but little is known about its value in CF. | Rumman et al. BMC Pediatrics 2014 14 133 http 1471-2431 14 133 BMC Pediatrics RESEARCH ARTICLE Open Access Calprotectin in Cystic Fibrosis Nisreen Rumman1 3 Mutaz Sultan2 3 Khalil El-Chammas2 5 Vi Goh2 4 Nita Salzman2 Diana Quintero1 and Steven Werlin2 Abstract Background There is increasing evidence that intestinal inflammation plays a major role in gastrointestinal symptoms in cystic fibrosis CF . Fecal calprotectin is a marker that is elevated in several gastrointestinal inflammatory diseases but little is known about its value in CF. We aimed to look for associations of elevated fecal calprotectin among CF patients and whether its level correlates with the clinical manifestations of CF. Methods A single stool specimen was collected from 62 patients with CF. Fecal calprotectin was measured using the commercially available ELISA kits PhiCal test . Clinical data were collected from patients records and CF registry. Results There were no significant differences between CF patients with normal and abnormal fecal calprotectin levels. However patients who were not receiving inhaled antibiotics had higher fecal calprotectin levels than those who were. Conclusion Elevated fecal calprotectin may not accurately predict intestinal inflammation in CF. However the fact that it was elevated in both pancreatic sufficient and insufficient groups supports the concept of cystic fibrosis enteropathy regardless of the pancreatic status. Background Cystic fibrosis CF is the most common cause of pancreatic insufficiency PI in children. Between 85 - 90 of CF patients have PI and malabsorption. These patients are typically treated with pancreatic enzyme replacement therapy PERT . However CF patients with pancreatic sufficiency PS and patients with PI who receive adequate PERT may have persistent abdominal symptoms. It has been suggested that other poorly understood non pancreatic confounding factors are likely contributors 1 . There is no specific noninvasive test